Ascidian Therapeutics Announces First-Ever FDA approval of their Investigational New Drug (IND) ACDN-01, which Targets Rare Genetic Eye Diseases
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Receives FDA Clearance for Phase I Trial of its CAR-T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iEcure Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
Penn Startups Recognized in Labiotech’s List of “Eight companies spearheading Philadelphia’s biotech industry”
After emerging from stealth mode in 2023, BlueWhale aims to develop a technology platform and product portfolio that will provide the benefits of cell therapy to patients more quickly.
The Chamber of Commerce for Greater Philadelphia Recognizes the Philadelphia Region as Leader in Cell and Gene Therapy
The report highlights Penn’s significant contributions to the growth of the CGT sector in Greater Philadelphia, including spinning out over 40 CGT companies since 2018.
Philadelphia Ranks 4th Among National Life Sciences Markets in New Colliers Report
In the recently released Colliers 2024 Life Sciences Report, Philadelphia ranked #4 nationwide, with Boston, the San Francisco Bay Area and San Diego ranking first, second and third, respectively.
2023 President’s Prize Winners: Where They Are Now?
The 2023 President’s Innovation Prize (PIP) and President’s Engagement Prize (PEP) winners have each made significant strides over the course of the past year.
LNP Research from the Mitchell Lab is Highlighted in the Philadelphia Inquirer
Mike Mitchell, PhD, was interviewed recently by the Philadelphia Inquirer about his cutting-edge research in lipid nanoparticles (LNPs), which are crucial for delivering mRNA into the body's cells.
Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.